45 results about "Serum insulin" patented technology

Novel dipeptide ethers are effective for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels. The dipeptide ethers are also useful for the treatment and / or prophylaxis of diabetes, obesity, inflammation and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and / or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and immunological diseases, including the treatment of cancer. Furthermore, the compounds are useful for the treatment of disorders associated with insulin resistance.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

This invention relates to one human serum insulin content and C-peptide chemical test method in clinical serum immune test technique, which uses human serum insulin quantitative test agent case to test human serum insulin content and human serum C-peptide agent case to test human serum C-peptide content.

Analysis of full-blood glucose, serum insulin, serum triglycerides and total serum cholesterol were performed. Glucose levels in blood samples from the oral glucose tolerance test were used for calculation of the incremental Area Under the Curve (AUC0-120 min-baseline). All data are expressed as percentage change of vehicle treated animals (cf. FIGS. 1 and 2).

The invention relates to the field of gene engineering, and discloses a construction and an expression for two engineering bacteria of two human glucagon-like peptide-1 analogues, and a preparation method for the objective peptides. The objective peptides are formed by inserting objective sequence after double digestions, adding His labels at the front ends of fusion proteins, obtaining objective peptides by cutting the fusion proteins with acid via gaining the fusion proteins, and after an isoelectric precipitation, obtaining the objective peptides again through an affinity chromatography of a Ni agarose gel after an isoelectric precipitation. Freeze-dried objective peptides are dissolved in a PBS buffer solution, oral glucose tolerance test and determination of serum insulin concentration are carried out on normal ICR mice. The two analogues are modified peptides of human glucagon-like peptide-1. Experiments demonstrate that both the two peptides have effects for reducing blood glucose and can be used for treating type 2 diabetes mellitus. Furthermore, the invention also provides the preparation method for the peptides.

The invention provides a method for constructing a related intestinal canal-pancreatic islet regulation axis function evaluation model. The method includes: allowing a subject to take different oral hypoglycemic drugs or blank control in different stages, then performing intravenous-oral dual hyperglycemic clamp tests on the subject in each stage, drawing an area under the curve for a serum insulin value, a C-peptide value, a plasma glucagon value and an active glucagon-like polypeptide-1 (GLP-1) value acquired through the dual hyperglycemic clamp tests in each stage, and applying Metlab to perform 3D (three-dimensional surface fitting on the areas under the curve in one-to-one correspondence to obtain the related intestine-pancreas axis function evaluation model. By the method, two-phase insulin secretion patterns in intravenous-oral glucose stimulation states can be evaluated and compared accurately, besides, intestinal canal hormone effect and insulin-glucagon secretion can be related quantitatively, and accordingly an accurate intestine-pancreas axis effect model evaluation system is obtained.

The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and / or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and immunological diseases, including the treatment of cancer. Furthermore, the compounds are useful for the treatment of disorders associated with insulin resistance.

Novel hydroxamic acid containing amino acid derivatives are provided that are useful for treatment of inflammation, inflammatory and immunological diseases; lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; and for treatment or prophylaxis of metabolic disorders.

The invention discloses bifidobacterium longum for relieving insulin resistance and application of the bifidobacterium longum, and belongs to the technical field of microorganisms. The bifidobacterium longum NSP008 disclosed by the invention can be used for inhibiting the increase of the body weight and the body fat of an insulin-resistant mouse on the premise of not influencing the food intake; the glucose tolerance of an insulin-resistant mouse is improved, and meanwhile, the blood sugar, serum insulin and an insulin resistance index of the mouse are reduced; the insulin-resistant mouse liver triglyceride and inflammation level can be adjusted, and liver tissue damage can be relieved; the intestinal flora structure is improved, and the growth of intestinal probiotics is promoted. The bifidobacterium longum NSP008 disclosed by the invention is used for preparing a pharmaceutical composition and fermented food for relieving insulin resistance, and has a very wide application prospect.

The invention discloses an application of lupenone to products for preventing or treating diabetes mellitus. Inventors deeply develop the lupenone by adopting the modern medicine efficacy and acute toxicity study technology. Pharmacodynamic experimental study shows that proper medicine can be processed and prepared from the lupenone as major ingredients and is used for preventing and treating the diabetes mellitus, the pharmacological activity is obvious, the performance is stable, safety and reliability are realized, the hyperglycemic effect is obvious, and phenomenon of serum insulin and C peptide rise caused by insulin resistance is also reduced, so the sugar tolerance is improved. In addition, the extraction raw material sources of the lupenone are easy to obtain, the preparation process easily realizes the industrialization, and medicine materials can be driven to be fully developed and utilized, so the lupenone has good application prospects in aspects of diabetes mellitus treatment medicine or health-care products.

The invention provides a compound shown in the formula I or pharmaceutically acceptable salts, hydrates or solvates thereof, and also provides new application of the compound or the pharmaceutically acceptable salts, hydrates or solvents thereof. A deuterated compound can be used for remarkably improving the conditions of the weight, fasting blood-glucose, transaminase and fasting serum insulin of an obese patient, increasing the insulin sensitivity can be improve, and enhancing the serum lipid parameter and oral glucose tolerance; the compound has the advantages that internal absorption effect is excellent;, the bioavailability is high, which is favorable for the taking of drug effect; the half-life period is prolonged, so that the administration frequency can be reduced and toxic and side effects can be reduced; therefore a new safe and reliable choice is provided to clinical administration. The formula I can be found in the specification.

The invention discloses an application of lupenone to products for preventing or treating diabetes mellitus. Inventors deeply develop the lupenone by adopting the modern medicine efficacy and acute toxicity study technology. Pharmacodynamic experimental study shows that proper medicine can be processed and prepared from the lupenone as major ingredients and is used for preventing and treating the diabetes mellitus, the pharmacological activity is obvious, the performance is stable, safety and reliability are realized, the hyperglycemic effect is obvious, and phenomenon of serum insulin and C peptide rise caused by insulin resistance is also reduced, so the sugar tolerance is improved. In addition, the extraction raw material sources of the lupenone are easy to obtain, the preparation process easily realizes the industrialization, and medicine materials can be driven to be fully developed and utilized, so the lupenone has good application prospects in aspects of diabetes mellitus treatment medicine or health-care products.

The present invention provides applications of a traditional Chinese medicine composition in preparation of blood glucose lowering drugs, wherein the traditional Chinese medicine composition comprises, by mass, 1-3 parts of Acanthopanax senticosus, 0.5-1.5 parts of Angelica sinensis, and 1-3 parts of Milkvetch Root. The present invention further provides applications of a composition in preparation of blood glucose lowering drugs, wherein the composition comprises, by mass, 1-3 parts of an Acanthopanax senticosus extract, 0.5-1.5 parts of an Angelica sinensis extract, and 1-3 parts of a Milkvetch Root extract. According to the present invention, Acanthopanax senticosus, Angelica sinensis and Milkvetch Root are used as the active components and are used for preparing blood glucose loweringdrugs; and the experimental results show that the traditional Chinese medicine composition can significantly reduce the fasting blood glucose of mice, reduce the glycated hemoglobin of diabetic mice,and increase the serum insulin secretion, and has obvious effect superior to the traditional Chinese medicine composition containing complex components, wherein the effect difference between the traditional Chinese medicine composition of the present invention and the traditional Chinese medicine composition containing complex components is significant (P < 0.05).

The invention provides a method for extracting fresh ginseng with superhigh pressure equipment. The method specially comprises the following steps of selecting good-quality fresh ginseng which is 4-5years old and has complete exteriority, adding water which is 0.5-1 time of the fresh ginseng, placing the ginseng and the water in a plastic bag, performing sealing, putting the plastic bag in a superhigh pressure cabin at the pressure of 400 MPa, performing extraction for 5 minutes, taking an extracting solution, and performing filtering to obtain a fresh ginseng extracting solution. In the extraction process, sample materials do not need to be crushed, the prototype of the entire fresh ginseng can be maintained, and the exteriority is intact, so that the nature of the ginseng exteriority asa natural filtration membrane can be used, substances with relative micromolecules can pass the exteriority, part of macromolecular compounds can be prevented from passing the exteriority, and a fresh ginseng stock solution is guaranteed to be clear and transparent. The fresh ginseng extracting solution can be used for preparing fresh ginseng oral liquid or beverages, and the made fresh ginseng oral liquid or beverages can obviously reduce the fasting blood sugar of mice suffering from diabetes, can obviously improve the oral sugar tolerance of the mice suffering from type II diabetes, and besides, cannot raise the level of serum insulin. The fresh ginseng extracting solution can be made into drugs, foods or health-care products for type II diabetes.

The invention belongs to the field of biomedicine and particularly relates to application of tea peptides to relieving diabetic nephropathy. Compared with the prior art, the application of the tea peptides to relieving diabetic nephropathy provides a new method and research theory for treating and relieving diabetic nephropathy; study and experiment shows that the tea peptides extracted from tea residues achieve good relieving effects on diabetic nephropathy to effectively reduce sugar content of blood, increase sensitivity of serum insulin and improve insulin resistance; besides, research anddevelopment of the tea peptides extracted from the tea residues is of significance and value to further deep study on tea functions, thereby having a broad potential marketing and application prospect.

Novel diphenylethylene and styrenes are provided which are administered orally to decrease blood glucose levels in rats. The glucose tolerance in insulin resistant rats is also shown, as well as lowering of triglyceride levels in serum insulin resistant, hyperinsulienmic and hypertriglycedmic rats. The compounds are orally effective anti-diabetic agents that potentially may reduce abnormality of glucose and lipid metabolism in diabetes.

The invention discloses a kit for measuring serum insulin. The kit comprises a kit body and a kit cover hinged to the kit body. A fixed frame is detachably mounted in an inner cavity of the kit body.A first accommodating cavity, a second accommodating cavity, a third accommodating cavity and a fourth accommodating cavity are formed in the fixed frame. A first reagent bottle is mounted in the first accommodating cavity. A second reagent bottle is mounted in the second accommodating cavity. A stirring device is arranged in the third accommodating cavity. A filter device is arranged in the fourth accommodating cavity. The kit has the technical effects that drugs are evenly mixed in agentia, and the purity of filtered agentia is higher, so that measurement accuracy is improved, and the cure rate of patients is increased.

Novel hydroxamic acid containing amino acid derivatives are provided that are useful for treatment of inflammation, inflammatory and immunological diseases; lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; and for treatment or prophylaxis of metabolic disorders.

The invention discloses a culture method for increasing the titer of porcine epidemic diarrhea viruses. The culture method includes the following steps: Vero cells are subjected to bottle-separation passage, and then inoculated into cell growth fluid containing newborn calf serum to be cultured to obtain a dense single layer; then the porcine epidemic diarrhea viruses are inoculated into the densesingle layer to be cultured to obtain a mixture; and maintenance media containing the newborn calf serum, insulin and trehalose are added into the mixture, rotating culture is conducted, when the lesion rate is greater than 80%, the viruses are obtained, and thus the porcine epidemic diarrhea viruses are obtained. The content of the viruses can be significantly increased, virus inactivation is avoided, and the problem of low virus titer is effectively solved.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The invention discloses a microscale serum insulin content detection device which includes a gas-control unit, a microfluidic integrated chip and a detection apparatus. The microfluidic integrated chip includes a glass base layer, a gas driving layer and a liquid flowing layer which are installed together in a successive manner from bottom to top. A mixer, a plurality of gas channel pipes, a plurality of structure gas chambers and a plurality of pneumatic micropumps are arranged on the gas driving layer and are communicated with each other. The gas channel pipes are communicated with the gas-control unit. A mixing pool, a plurality of fluid channels and a plurality of micro liquid storage pools are arranged on the liquid flowing layer, wherein the number of the fluid channels and the number of the micro liquid storage pools are corresponding to the number of the structure gas chambers. Each fluid channel is communicated with each micro liquid storage pool. The detection apparatus includes a photomultiplier. The device is small in size, little in blood consumption, low in cost, high in detection speed and high in sensitivity. The device has great significances of achieving popularized diabetes screening and early-stage diagnosis and medical treatment and reducing harms of large-scale epidemic diseases on human society.

The invention discloses a traditional Chinese medicine composition for treating diabetes. The traditional Chinese medicine composition comprises 10-20g of fragrant solomonseal rhizome, 10-20g of glossy privet fruit, 10-20g of glutinous rice, 10-20g of gypsum, 10-20g of heterophylly falsestarwort root, 10-20g of costustoot, 5-10g of oriental waterplantain rhizome, 5-10g of mongolian dandelion herb and 5-10g of dendrobium. The traditional Chinese medicine composition disclosed by the invention has the fasting blood-glucose curative effect significant efficiency of 32.1-53.5% and the postprandial blood sugar significant efficiency of 38.2-63.2% after treating diabetes on the basis of the principle of resolving the current problems and eliminating the root causes in traditional Chinese medicines, has a certain repairing effect on pancreatic tissue damages caused by tetraoxypyrimidine, has a certain increase tread on insulin release of diabetic patients after treatment, has significantly-increased postprandial serum insulin, and obviously improves the diabetes symptoms. Clinical experiments show that the traditional Chinese medicine composition disclosed by the invention is safe in taking and reliable in curative effect, and can not cause abnormal influences and other adverse reactions and side or toxic effects on the heart, liver and kidney functions and blood systems.

Described are novel compounds of the Formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and / or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors.

star fruit, which is also called carambola fruit, belongs to oxalidaceae plants. On the basis of a great amount of pharmacodynamics studies on sour carambola fruits for a long term, a total extract of the sour carambola fruits, upon studies, is proved to be significant in therapeutic effect on mice with streptozotocin-induced diabetes mellitus, and the total extract is capable of obviously reducing a blood glucose level, increasing a serum insulin concentration, improving a renal function, improving glucose tolerance, increasing hepatic glycogen content and SOD (superoxide dismutase) activity in liver tissues and reducing MDA (methane dicarboxylic aldehyde) activity in the liver tissues. The invention can provide a novel medicine for resisting diabetes mellitus to patients with the diabetes mellitus.